Compare ESTA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | HRMY |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Costa Rica | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2018 | 2020 |
| Metric | ESTA | HRMY |
|---|---|---|
| Price | $68.12 | $36.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $78.86 | $49.75 |
| AVG Volume (30 Days) | 416.3K | ★ 651.2K |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | $190,973,000.00 | ★ $825,944,000.00 |
| Revenue This Year | $29.17 | $23.29 |
| Revenue Next Year | $25.05 | $15.98 |
| P/E Ratio | ★ N/A | $11.43 |
| Revenue Growth | ★ 24.76 | 21.13 |
| 52 Week Low | $26.56 | $25.52 |
| 52 Week High | $78.24 | $40.93 |
| Indicator | ESTA | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 44.31 |
| Support Level | $63.47 | $34.68 |
| Resistance Level | $68.98 | $39.40 |
| Average True Range (ATR) | 4.01 | 1.32 |
| MACD | -0.88 | -0.33 |
| Stochastic Oscillator | 34.37 | 32.84 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.